Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23267237 | 0.75 | GAA (0.40) | GAAMAPK1 | |
| SCHEMBL13901030 | 0.75 | KDM4E (0.36) | GAA | |
| SCHEMBL24179908 | 0.75 | CYP2D6 (0.37) | — | |
| SCHEMBL129344 | 0.74 | — | — | |
| SCHEMBL14767403 | 0.72 | — | — | |
| SCHEMBL1515058 | 0.70 | — | — | |
| SCHEMBL20411473 | 0.70 | GAA (0.33) | GAAMAPK1 | |
| SCHEMBL3813753 | 0.70 | TET3 (0.34) | — | |
| SCHEMBL130275 | 0.69 | — | — | |
| SCHEMBL132084 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116400-A1 | Oxazolidinone and/or isoxazoline derivatives as antibacterial agents | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | US | disclosed |
| CN-1742015-A | Oxazolidinone and / or isoxazoline derivatives as antibacterial agents | ASTRAZENECA AB (SE) | 2006-03-01 | — | — | CN | disclosed |
| EP-1567532-A1 | OXAZOLIDINONE AND / OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | Astrazeneca AB (SE) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004048392-A1 | OXAZOLIDINONE AND / OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116400-A1 | Oxazolidinone and/or isoxazoline derivatives as antibacterial agents | NR0B2, NR0B1, HRH2 | GAA 4091/4885MAPK1 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.